Abstract
Insulin therapy is an inseparable part of the treatment of patients with type 1 diabetes and also of many patients with type 2 diabetes, in particular those with longer disease duration. In many patients with type 2 diabetes, insulin therapy is often initiated later than optimal.
One of the reasons is suboptimal pharmacokinetics of the currently available insulins. This is why there is an intensive effort aiming at the development of novel insulins with improved characteristics closer to physiological regulation of insulin secretion.
The aim of this paper is to summarize the current knowledge concerning new insulins that have been recently introduced or will be soon introduced into the market. We will also discuss the perspectives of insulin therapy in the longer-term horizon including the efforts of development of insulins with alternative route of administration.